# Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

> **NCT02378961** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 128 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** VOX
- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT02378961
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-16
- **Primary completion:** 2015-09-21
- **Final completion:** 2016-01-26
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378961, "Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT02378961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*